SumanaDevataMD
Hematology • Milwaukee, WIHematologic Oncology
Hematology/Oncology, University of Michigan
Dr. Devata is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9200 W Wisconsin Ave
Milwaukee, WI 53226Phone+1 414-805-4600Fax+1 414-805-4602
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 2012 - 2015
Medical College of Wisconsin Affiliated HospitalsResidency, Internal Medicine, 2008 - 2011
Loyola University Chicago Stritch School of MedicineClass of 2008
Certifications & Licensure
WI State Medical License 2010 - 2025
MI State Medical License 2012 - 2022- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 45 citationsPhase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell LymphomaAuris Huen, Bradley M. Haverkos, Jasmine Zain, Ramchandren Radhakrishnan, Mary Jo Lechowicz
Cancers. 2020-08-15 - 16 citationsPerforming and processing FNA of anterior fat pad for amyloidVinod B. Shidham, Bryan Hunt, Safwan Jaradeh, Alexandru Barboi, Sumana Devata
Journal of Visualized Experiments. 2010-10-30 - 21 citationsDetection of amyloid in abdominal fat pad aspirates in early amyloidosis: Role of electron microscopy and Congo red stained cell block sectionsSumana Devata, Parameswaran Hari, Natalia Markelova, Rongshan Li, Richard A. Komorowski
Cytojournal. 2011-01-01
Abstracts/Posters
- Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K _/_ Inhibitor in Patients with Relapsed/Refractory T-Cell LymphomaSumana Devata, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Cen...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymph...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Contemporary Treatment Options for a Classical Disease: Advanced Hodgkin LymphomaFebruary 13th, 2020
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
